Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 4/2012

01-08-2012

Connexin43 Modulation Inhibits Scarring in a Rabbit Eye Glaucoma Trabeculectomy Model

Authors: Narmadai C. Deva, Jie Zhang, Colin R. Green, Helen V. Danesh-Meyer

Published in: Inflammation | Issue 4/2012

Login to get access

Abstract

We investigated whether one subconjunctival injection of connexin43 antisense oligodeoxynucleotides (Cx43 AsODN) modulates postoperative scarring in a rabbit model of glaucoma trabeculectomy surgery. In a randomised, controlled, masked-observer study, 39 rabbits underwent trabeculectomy surgery with insertion of a 22-gauge cannula in the right eyes and were randomly divided into three treatment groups. Each rabbit received an injection of Cx43 AsODN in Pluronic gel, balanced salt solution or Pluronic gel alone into the formed bled. The animals were euthanized at 8 and 24 h and at 5 and 21 days. Histology and immunohistochemistry results demonstrated that Cx43 AsODN decreased Cx43 upregulation at 8 and 24 h which led to less myofibroblast upregulation at days 5 and 21 and reduced scarring at day 21 compared to controls. We conclude that postoperative use of Cx43 AsODN inhibited subconjunctival scarring and fibrosis. Cx43 AsODN injection may be a safe and effective anti-scarring agent in glaucoma trabeculectomy surgery.
Literature
1.
Quigley, H.A., and A.T. Broman. 2006. The number of people with glaucoma worldwide in 2010 and 2020. British Journal of Ophthalmology 90: 262–267.PubMedCrossRef
2.
3.
Cairns, J.E. 1968. Trabeculectomy. Preliminary report of a new method. American Journal of Ophthalmology 66: 673–679.PubMed
4.
Skuta, G.L., and R.K. Parrish 2nd. 1987. Wound healing in glaucoma filtering surgery. Survey of Ophthalmology 32: 149–170.PubMedCrossRef
5.
Addicks, E.M., H.A. Quigley, W.R. Green, and A.L. Robin. 1983. Histologic characteristics of filtering blebs in glaucomatous eyes. Archives of Ophthalmology 101: 795–798.PubMedCrossRef
6.
Migdal, C., and R. Hitchings. 1983. The developing bleb: Effect of topical antiprostaglandins on the outcome of glaucoma fistulising surgery. British Journal of Ophthalmology 67: 655–660.PubMedCrossRef
7.
Messmer, E.M., D.M. Zapp, M.J. Mackert, M. Thiel, and A. Kampik. 2006. In vivo confocal microscopy of filtering blebs after trabeculectomy. Archives of Ophthalmology 124: 1095–1103.PubMedCrossRef
8.
Jones, E., J. Clarke, and P.T. Khaw. 2005. Recent advances in trabeculectomy technique. Current Opinion in Ophthalmology 16: 107–113.PubMedCrossRef
9.
Khaw, P.T., M.B. Sherwood, J.W. Doyle, M.F. Smith, I. Grierson, S. McGorray, and G.S. Schultz. 1992. Intraoperative and post operative treatment with 5-fluorouracil and mitomycin-c: Long term effects in vivo on subconjunctival and scleral fibroblasts. International Ophthalmology 16: 381–385.PubMedCrossRef
10.
Khaw, P.T., J.W. Doyle, M.B. Sherwood, I. Grierson, G. Schultz, and S. McGorray. 1993. Prolonged localized tissue effects from 5-minute exposures to fluorouracil and mitomycin C. Archives of Ophthalmology 111: 263–267.PubMedCrossRef
11.
Greenfield, D.S., J.M. Liebmann, J. Jee, and R. Ritch. 1998. Late-onset bleb leaks after glaucoma filtering surgery. Archives of Ophthalmology 116: 443–447.PubMed
12.
Higginbotham, E.J., R.K. Stevens, D.C. Musch, K.O. Karp, P.R. Lichter, T.J. Bergstrom, and G.L. Skuta. 1996. Bleb-related endophthalmitis after trabeculectomy with mitomycin C. Ophthalmology 103: 650–656.PubMed
13.
Bindlish, R., G.P. Condon, J.D. Schlosser, J. D’Antonio, K.B. Lauer, and R. Lehrer. 2002. Efficacy and safety of mitomycin-C in primary trabeculectomy: Five-year follow-up. Ophthalmology 109: 1336–1341. discussion 1341–2.PubMedCrossRef
14.
Evans, W.H., E. De Vuyst, and L. Leybaert. 2006. The gap junction cellular internet: Connexin hemichannels enter the signalling limelight. Biochemical Journal 397: 1–14.PubMedCrossRef
15.
Goodenough, D.A., J.A. Goliger, and D.L. Paul. 1996. Connexins, connexons, and intercellular communication. Annual Review of Biochemistry 65: 475–502.PubMedCrossRef
16.
Bruzzone, R., T.W. White, and D.A. Goodenough. 1996. The cellular internet: On-line with connexins. Bioessays 18: 709–718.PubMedCrossRef
17.
18.
Beyer, E.C., and T.H. Steinberg. 1991. Evidence that the gap junction protein connexin-43 is the ATP-induced pore of mouse macrophages. Journal of Biological Chemistry 266: 7971–7974.PubMed
19.
Oviedo-Orta, E., P. Gasque, and W.H. Evans. 2001. Immunoglobulin and cytokine expression in mixed lymphocyte cultures is reduced by disruption of gap junction intercellular communication. The FASEB Journal 15: 768–774.CrossRef
20.
Oviedo-Orta, E., T. Hoy, and W.H. Evans. 2000. Intercellular communication in the immune system: Differential expression of connexin40 and 43, and perturbation of gap junction channel functions in peripheral blood and tonsil human lymphocyte subpopulations. Immunology 99: 578–590.PubMedCrossRef
21.
Kwak, B.R., M.S. Pepper, D.B. Gros, and P. Meda. 2001. Inhibition of endothelial wound repair by dominant negative connexin inhibitors. Molecular Biology of the Cell 12: 831–845.PubMed
22.
Oviedo-Orta, E., R.J. Errington, and W.H. Evans. 2002. Gap junction intercellular communication during lymphocyte transendothelial migration. Cell Biology International 26: 253–263.PubMedCrossRef
23.
Ehrlich, H.P., G. Gabbiani, and P. Meda. 2000. Cell coupling modulates the contraction of fibroblast-populated collagen lattices. Journal of Cellular Physiology 184: 86–92.PubMedCrossRef
24.
Coutinho, P., C. Qiu, S. Frank, C.M. Wang, T. Brown, C.R. Green, and D.L. Becker. 2005. Limiting burn extension by transient inhibition of connexin43 expression at the site of injury. British Journal of Plastic Surgery 58: 658–667.PubMedCrossRef
25.
Qiu, C., P. Coutinho, S. Frank, S. Franke, L.Y. Law, P. Martin, C.R. Green, and D.L. Becker. 2003. Targeting connexin43 expression accelerates the rate of wound repair. Current Biology 13: 1697–1703.PubMedCrossRef
26.
Mori, R., K.T. Power, C.M. Wang, P. Martin, and D.L. Becker. 2006. Acute downregulation of connexin43 at wound sites leads to a reduced inflammatory response, enhanced keratinocyte proliferation and wound fibroblast migration. Journal of Cell Science 119: 5193–5203.PubMedCrossRef
27.
Cronin, M., P.N. Anderson, J.E. Cook, C.R. Green, and D.L. Becker. 2008. Blocking connexin43 expression reduces inflammation and improves functional recovery after spinal cord injury. Molecular and Cellular Neuroscience 39: 152–160.PubMedCrossRef
28.
Danesh-Meyer, H.V., R. Huang, L.F.B. Nicholson, and C.R. Green. 2008. Connexin43 antisense oligodeoxynucleotide treatment down-regulates the inflammatory response in an in vitro interphase organotypic culture model of optic nerve ischaemia. Journal of Clinical Neuroscience 15: 1253–1263.PubMedCrossRef
29.
Cordeiro, M.F., P.H. Constable, R.A. Alexander, S.S. Bhattacharya, and P.T. Khaw. 1997. Effect of varying the mitomycin-C treatment area in glaucoma filtration surgery in the rabbit. Investigative Ophthalmology & Visual Science 38: 1639–1646.
30.
Green, C.R., L.Y. Law, J.S. Lin, and D.L. Becker. 2001. Spatiotemporal depletion of connexins using antisense oligonucleotides. Methods in Molecular Biology 154: 175–185.PubMed
31.
Law, L.Y., W.V. Zhang, N.S. Stott, D.L. Becker, and C.R. Green. 2006. In vitro optimization of antisense oligodeoxynucleotide design: An example using the connexin gene family. Journal of Biomolecular Techniques 17: 270–282.PubMed
32.
Ratkay-Traub, I., B. Hopp, Z. Bor, L. Dux, D.L. Becker, and T. Krenacs. 2001. Regeneration of rabbit cornea following excimer laser photorefractive keratectomy: A study on gap junctions, epithelial junctions and epidermal growth factor receptor expression in correlation with cell proliferation. Experimental Eye Research 73: 291–302.PubMedCrossRef
33.
Darby, I., O. Skalli, and G. Gabbiani. 1990. Alpha-smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. Laboratory Investigation 63: 21–29.PubMed
34.
35.
Dayan, D., Y. Hiss, A. Hirshberg, J.J. Bubis, and M. Wolman. 1989. Are the polarization colors of picrosirius red-stained collagen determined only by the diameter of the fibers? Histochemistry 93: 27–29.PubMedCrossRef
36.
Bergstrom, T.J., W.S. Wilkinson, G.L. Skuta, R.L. Watnick, and V.M. Elner. 1991. The effects of subconjunctival mitomycin-C on glaucoma filtration surgery in rabbits. Archives of Ophthalmology 109: 1725–1730.PubMedCrossRef
37.
Akman, A., B. Bilezikci, C. Kucukerdonmez, B. Demirhan, and P. Aydin. 2003. Suramin modulates wound healing of rabbit conjunctiva after trabeculectomy: Comparison with mitomycin C. Current Eye Research 26: 37–43.PubMedCrossRef
38.
Wong, T.T.L., A.L. Mead, and P.T. Khaw. 2005. Prolonged antiscarring effects of ilomastat and MMC after experimental glaucoma filtration surgery. Investigative Ophthalmology & Visual Science 46: 2018–2022.CrossRef
39.
Memarzadeh, F., R. Varma, L.-T. Lin, J.G. Parikh, L. Dustin, A. Alcaraz, and D. Eliott. 2009. Postoperative Use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Investigative Ophthalmology & Visual Science 50: 3233–3237.CrossRef
40.
Mead, A.L., T.T.L. Wong, M.F. Cordeiro, I.K. Anderson, and P.T. Khaw. 2003. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Investigative Ophthalmology & Visual Science 44: 3394–3401.CrossRef
41.
Takeuchi, K., M. Nakazawa, Y. Ebina, K. Sato, T. Metoki, Y. Miyagawa, and T. Ito. 2010. Inhibitory effects of trehalose on fibroblast proliferation and implications for ocular surgery. Experimental Eye Research 91: 567–577.PubMedCrossRef
42.
Wong, T.T.L., A.L. Mead, and P.T. Khaw. 2003. Matrix metalloproteinase inhibition modulates postoperative scarring after experimental glaucoma filtration surgery. Investigative Ophthalmology & Visual Science 44: 1097–1103.CrossRef
43.
Risek, B., F.G. Klier, and N.B. Gilula. 1994. Developmental regulation and structural organization of connexins in epidermal gap junctions. Developmental Biology 164: 183–196.PubMedCrossRef
44.
Chin, K.Y. 2011. Connexins, a new target in wound treatment. Journal of Wound Care 20: 386–390.PubMed
45.
Brandner, J.M., P. Houdek, B. Husing, C. Kaiser, and I. Moll. 2004. Connexins 26, 30, and 43: Differences among spontaneous, chronic, and accelerated human wound healing. Journal of Investigative Dermatology 122: 1310–1320.PubMedCrossRef
46.
Wang, C.M., J. Lincoln, J.E. Cook, and D.L. Becker. 2007. Abnormal connexin expression underlies delayed wound healing in diabetic skin. Diabetes 56: 2809–2817.PubMedCrossRef
47.
Li, Z., T. Van Bergen, S. Van de Veire, I. Van de Vel, H. Moreau, M. Dewerchin, P.C. Maudgal, T. Zeyen, W. Spileers, L. Moons, and I. Stalmans. 2009. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Investigative Ophthalmology & Visual Science 50: 5217–5225.CrossRef
48.
Cordeiro, M.F., J.A. Gay, and P.T. Khaw. 1999. Human anti-transforming growth factor-beta2 antibody: A new glaucoma anti-scarring agent. Investigative Ophthalmology & Visual Science 40: 2225–2234.
49.
Seetner, A., and J.D. Morin. 1979. Healing of trabeculectomies in rabbits. Canadian Journal of Ophthalmology 14: 121–125.PubMed
Metadata
Title
Connexin43 Modulation Inhibits Scarring in a Rabbit Eye Glaucoma Trabeculectomy Model
Authors
Narmadai C. Deva
Jie Zhang
Colin R. Green
Helen V. Danesh-Meyer
Publication date
01-08-2012
Publisher
Springer US
Published in
Inflammation / Issue 4/2012
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-012-9439-4

Other articles of this Issue 4/2012

Inflammation 4/2012 Go to the issue

OriginalPaper

Pharmacological and Pharmacokinetic Studies with Agaricoglycerides, Extracted from Grifola frondosa, in Animal Models of Pain and Inflammation

OriginalPaper

Plasma Melatonin and Urinary 6-Hydroxymelatonin Levels in Patients with Pulmonary Tuberculosis

OriginalPaper

Anti-inflammatory Effect of Piperine in Adjuvant-Induced Arthritic Rats—a Biochemical Approach

OriginalPaper

Allopurinol Ameliorates Thioacetamide-Induced Acute Liver Failure by Regulating Cellular Redox-Sensitive Transcription Factors in Rats

OriginalPaper

HSF1 Is a Transcriptional Activator of IL-10 Gene Expression in RAW264.7 Macrophages

OriginalPaper

Comparison of Quantiferon Test with Tuberculin Skin Test for the Detection of Tuberculosis Infection in Children
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits